Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
February 9th, 2024
Here, we show the procedures for FAM83A knockdown; the assays to detect its effects on proliferation, migration, and invasion of cervical cancer cells; and the sensitization of these cells to cisplatin. This study provides a promising target gene for cervical cancer and a reference for further drug research.
The scope of our research and focus are the investigating the role of FAM83A in cervical cancer cell growth and cisplatin sensitivity. By addressing this question, we hope to contribute to the scientific understanding of the cervical cancer biology and potentially identify new therapeutic targets for this disease. We found lysing FAM83A expressions desensitizes cervical cancer cells to cisplatin treatment, enhancing the drug's cytotoxic effect and inhibiting the cell viability and migration.
Our laboratory will focus on the foreign research question in the future, illustrating the medical mycolysis of FAM83A in cervical cancer, developing FAM83A inhibitors or activators therapies, starting the correlation between FAM83A and the patient prophylaxis and investigating the role of FAM83A in other types of cancer. To begin cell transfection, seed human cervical tumor cells in six-well plates. Prepare a mixture of 50 nanomolar cypham 83A and eight microliters of transfection agent in serum-free DMEM, then add 500 microliters of the mixture to the plate.
To the negative control, add only the serum-free DMEM. Now, replace the medium with one milliliter of fetal calf serum-supplemented DMEM. After 48 hours, treat the cells with one milliliter of five micromolar cisplatin for 24 hours, then harvest the cells for total RNA extraction and qRT-PCR analysis.
Wash the above treated cells with ice cold PBS to remove any residual media and add 50 microliters of the RIPA lysis buffer containing PMSF to lyse the cells. Collect the cells in a tube. Incubate the cells on ice for a few minutes to ensure complete lysis, then centrifuge at four degrees Celsius at 12, 000 G for 15 minutes.
Then, mix the cell lysate with a loading buffer and heat the mixture at 95 to 100 degrees Celsius for five to 10 minutes on a water bath to denature the proteins. Load 10 microliters of total protein from each sample onto an SDS-PAGE gel. Run the gel under a constant voltage of 80 volts.
Stop the electrophoresis when the bromophenol blue reaches the bottom of the separation gel, then use a wet transfer system in an ice bath to transfer the separated proteins from the gel onto a polyvinylidene difluoride membrane. After the completion of the transfer, remove the membrane and incubate the membrane in a blocking buffer at room temperature for about one hour. Incubate the membrane with a secondary antibody conjugated to HRP.
Visualize the protein bands on the membrane using a chemiluminescent substrate and capture the signal using a chemiluminescence imaging system. Western blot analysis showed that the suppressed expression of FAM83A increased the BAX and cleaved caspase-three proteins, decreased the expression of BCL2, and increased cytochrome c release.
Overview
This study investigates the role of FAM83A in cervical cancer cell growth and its impact on cisplatin sensitivity. The findings suggest that targeting FAM83A may enhance the effectiveness of cisplatin in treating cervical cancer.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Cell Biology
Background
- Cervical cancer remains a significant health challenge.
- Cisplatin is a common chemotherapeutic agent used in treatment.
- Understanding gene targets like FAM83A can lead to improved therapies.
- Previous studies have indicated a potential role of FAM83A in cancer biology.
Purpose of Study
- To investigate the effects of FAM83A knockdown on cervical cancer cell proliferation.
- To assess the impact of FAM83A on cisplatin sensitivity.
- To identify potential therapeutic targets for cervical cancer treatment.
Methods Used
- Knockdown of FAM83A expression in cervical cancer cells.
- Assays to measure cell proliferation, migration, and invasion.
- Evaluation of cisplatin sensitivity in treated cells.
- Cell transfection procedures using specific reagents.
Main Results
- FAM83A knockdown desensitizes cervical cancer cells to cisplatin.
- Enhanced cytotoxic effects of cisplatin were observed.
- Cell viability and migration were significantly inhibited.
- Potential for developing FAM83A-targeted therapies was identified.
Conclusions
- FAM83A is a promising target for enhancing cervical cancer treatment.
- Further research is needed to explore FAM83A in other cancer types.
- The study provides a foundation for future drug development efforts.
Frequently Asked Questions
Executive Industry Relevance
Targeting FAM83A in cervical cancer models enables mechanistic de-risking of tumor growth pathways and chemotherapeutic response. Quantitative knockdown and phenotypic assays clarify FAM83A's role in modulating cisplatin sensitivity, supporting predictive confidence for target validation. These insights inform early portfolio triage and prioritization of FAM83A as a candidate for therapeutic intervention.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Functional knockdown of FAM83A interrogates its role in tumor cell proliferation and survival.
- Quantitative protein and phenotypic readouts provide biological de-risking for target validation.
- Data support predictive confidence in FAM83A as a modulator of chemotherapeutic response.
- Target validation informs go/no-go decisions for further therapeutic development.
Screening & Assay Development
- Validated siRNA knockdown and EdU proliferation assays enable standardized screening workflows.
- Migration and invasion assays establish reproducible, quantitative outputs for compound evaluation.
- Western blot and JC-1 staining provide robust analytical endpoints for apoptosis and mitochondrial function.
- Assay platforms are adaptable for high-throughput screening of FAM83A modulators.
Translational & Preclinical Research
- Phenotypic assays in HeLa and C33a cells model disease-relevant systems for translational alignment.
- Cisplatin sensitivity testing bridges discovery findings to preclinical therapeutic evaluation.
- Quantitative biomarker analysis supports continuity from target validation to preclinical studies.
- Mechanistic insights into apoptosis pathways inform risk-adjusted advancement decisions.
Pipeline & Workflow Integration
The FAM83A knockdown workflow integrates from early discovery through preclinical model validation, supporting lead identification and translational research.
- Discovery Biology: Enables hypothesis testing of FAM83A's role in tumor growth and drug response.
- Screening: Provides reproducible, quantitative assays for evaluating FAM83A-targeted interventions.
- Analytics: Delivers protein, apoptosis, and proliferation measurements for comparative analysis.
- Translational Research: Aligns in vitro findings with preclinical therapeutic evaluation using cisplatin sensitivity.
- Enterprise Reuse: Establishes a reusable platform for FAM83A functional interrogation across cancer models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in FAM83A as a therapeutic target and clarifies mechanistic pathways.
- Operational Value: Standardizes phenotypic and molecular assays for reproducibility and scalability.
- Strategic Value: Supports informed go/no-go decisions and reduces late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization of FAM83A-targeted programs.
Implementation Considerations
- Requires expertise in siRNA transfection, cell culture, and quantitative molecular assays.
- Demands access to flow cytometry, chemiluminescence imaging, and protein analysis infrastructure.
- Standardization of assay protocols is critical for cross-team reproducibility.
- Adaptation to additional cancer cell models may require protocol optimization.
- Phenotypic outputs are limited to in vitro systems and require further in vivo validation for translational advancement.
